Core Viewpoint - Elite Express Holding Inc. reported a transformational fiscal year 2025, marked by a successful transition to a publicly listed company and a revenue increase, despite a net loss due to higher operational costs and investments in compliance and development [3][4]. Financial Performance - For the fiscal year ended November 30, 2025, the company reported revenue of approximately $2.7 million, a 9.1% increase from $2.5 million in 2024 [2][5]. - The company recorded a net loss of approximately $2.2 million, compared to a net loss of $0.4 million in 2024, primarily due to increased general and administrative expenses and new research and development investments [12][2]. Revenue Breakdown - Activity-based revenue accounted for approximately $2.0 million, or 75.7% of total revenue, reflecting a focus on operational throughput under the FedEx ISP structure [5]. - Fixed revenue decreased from approximately $0.7 million to $0.6 million, a decline of 7.8%, attributed to a reduction in baseline weekly compensation [5]. Cost Structure - The cost of revenue for the fiscal year was approximately $2.6 million, up from $2.4 million in 2024, mainly due to higher labor costs and maintenance fees, partially offset by lower fuel prices [6]. - General and administrative expenses surged by approximately $1.2 million, or 286.1%, to $1.6 million, driven by legal and accounting fees related to the public company transition [8]. Research and Development - Research and development expenses totaled $0.9 million for the fiscal year, reflecting the company's strategic investment in a B2B delivery aggregation platform [9]. Loans and Interest Income - The company originated loans receivable totaling $10.0 million, generating interest income of $191,475 for the year, with loans extended to unrelated third-party business partners [10][11].

CHANDLER, Ariz., Feb. 27, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:MCHP) – Microchip Technology Incorporated, a leading provider of smart, connected, and secure embedded control solutions, today announced that the Company will present at the Raymond James Institutional Investors Conference on Monday, March 2, 2026 at 1:05 p.m. (Eastern Time). Presenting for the Company will be Mr. Sajid Daudi, Head of Investor Relations. A live webcast of the presentation will be made available by Raymond James, and can be accessed ...

CHANDLER, Ariz., Feb. 27, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:MCHP) – Microchip Technology Incorporated, a leading provider of smart, connected, and secure embedded control solutions, today announced that the Company will present at the Morgan Stanley Technology, Media & Telecom Conference on Tuesday March 3, 2026 at 1:05 p.m. (Pacific Time). Presenting for the Company will be Mr. Richard Simoncic, Chief Operating Officer, and Mr. Eric Bjornholt, Senior Vice President and Chief Financial Officer. A live webcas ...

ATLANTA, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Acuity Inc. (NYSE: AYI) (the “Company”) will release fiscal 2026 second-quarter results on Thursday, April 2, 2026 at 6:00 a.m. ET, followed by a conference call at 8:00 a.m. ET. Neil Ashe, Chief Executive Officer of Acuity Inc., will lead the call. The webcast, earnings release, and supplemental presentation can be accessed via the Investor Relations section of the Company's website at www.investors.acuityinc.com on Thursday, April 2, 2026. The online replay will ...

BOCA RATON, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- ADT Inc. (NYSE: ADT) today announced that its board of directors has approved the grant of equity awards in connection with ADT’s acquisition of Origin Wireless, Inc., a privately held company that specializes in AI-enabled WiFi sensing technology (“Origin”), in reliance on the employment inducement awards exemption under the NYSE’s Listed Company Manual Rule 303A.08. The board approved the grant of equity awards representing 8,070,357 shares of ADT common ...

SOUTHFIELD, Mich., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Methode Electronics, Inc. (NYSE: MEI), a leading global supplier of custom-engineered solutions for user interface, lighting, and power distribution applications, announced it will conduct a conference call and webcast on Friday, March 6, 2026, at 11:00 a.m. EST to review its third quarter fiscal 2026 results. President and Chief Executive Officer, Jon DeGaynor, and Chief Financial Officer, Laura Kowalchik will lead the call. The presentation will be webc ...

DOVER, Del., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Tidewater Utilities, Inc. (Tidewater), a water service provider and wholly owned subsidiary of Middlesex Water Company, today announced that it has received approval from the Delaware Public Service Commission (PSC) to refund approximately $1.1 million to customers through a one-time bill credit. The refund is funded by proceeds Tidewater received from litigation addressing per- and polyfluoroalkyl substances (“PFAS”) contamination. Tidewater will issue the one ...

Malaysia, Kuala Lumpur, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Megan Holdings Limited (Nasdaq: MGN) (the “Company” or “Megan”), a Malaysia-based company principally engaged in the development, construction, and maintenance of aquaculture farms and related works, today announced the closing of its follow-on public offering (the “Offering”) of 20,750,000 Class A ordinary shares, par value US$0.0001 per share, at a public offering price of US$0.40 per share. Gross proceeds to the Company, before deducting placement ...

SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial. The HERO trial is a Phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ARD- ...

TORONTO and HAIFA, Israel, Feb. 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announced today its participation in two international conferences taking place in March 2026. Dr. Lior Shaltiel, PhD, Chief Executive Officer of NurExone, commented, “Engaging with scientific, industry, and investor audiences is a core part of our strategy, and March includes two ...